Ads
related to: 23andme problems
Search results
Results From The WOW.Com Content Network
Despite operating for nearly two decades without profit, 23andMe went public in 2021 and reached a $6 billion valuation. The company's stocks were priced at $11.13 a share, but they've fallen ...
The financial struggles of genetic testing and ancestry company 23andMe are raising questions about the security of customers' DNA and other data. On Tuesday, 23andMe released its latest earnings ...
But 23andMe’s core business featured a fundamental flaw: Once people had their genomic data, they didn’t need to perform the test—or pay 23andMe—again. Another problem popped up in 2013 ...
DNA-testing service 23andMe is making substantial efforts to nurse its feeble genetic core back to health. The company will lay off 40% of its workforce, over 200 employees, and cull its therapy ...
The 23andMe data leak was a data breach at personal genomics company 23andMe reported in October 2023. The cyberattack gathered profile and ethnicity information from millions of users. The affected customers were reported as primarily Ashkenazi Jews but also including hundreds of thousands of ethnically Chinese users. [ 1 ]
23andMe went public in June 2021, a few months before the Lemonaid deal closed, at $11.13 a share. Since then, 23andMe's stock price has tumbled, partly because of a massive data breach and a ...
A class action lawsuit, resignations, layoffs, and other problems have plagued 23andMe. The company's issues have led to consumer concerns about how it handles genealogy data.
Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing further development of all its therapies as part of a restructuring ...